Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses

Journal of Clinical Oncology

Volumn 21, Issue 17, 2003, Pages 3310-3317

  Oldenburg, Jan ^a   Alfsen, G Cecilie ^a   Lien, Hans H ^a   Aass, Nina ^a   Wæhre, Håkon ^a   Fosså, Sophie D ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; ETOPOSIDE; IFOSFAMIDE;

ARTICLE; CONTROLLED STUDY; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; RETROPERITONEUM; RHABDOMYOSARCOMA; TERATOMA; TESTIS CANCER; ADOLESCENT; ADULT; CANCER STAGING; CHI SQUARE DISTRIBUTION; COMPUTER ASSISTED TOMOGRAPHY; LYMPHADENECTOMY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; NONPARAMETRIC TEST; PERITONEUM; RADIOGRAPHY; TESTIS TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; CHI-SQUARE DISTRIBUTION; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; HUMANS; IFOSFAMIDE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; PERITONEUM; STATISTICS, NONPARAMETRIC; TESTICULAR NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0141465121     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.184     Document Type: Article

References (37)

1. Steyerberg EW, Keizer HJ, Fossa SD, et al: Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups. J Clin Oncol 13:1177-1187, 1995
2. Baniel J, Foster RS, Rowland RG, et al: Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153:976-980, 1995
3. Gels ME, Nijboer AP, Hoekstra HJ, et al: Complications of the post-chemotherapy resection of retroperitoneal residual tumour mass in patients with non-seminomatous testicular germ cell tumours. Br J Urol 79:263-268, 1997
4. Nijman JM, Schraffordt-Koops H, Oldhoff J, et al: Sexual function after bilateral retroperitoneal lymph node dissection for nonseminomatous testicular cancer. Arch Androl 18:255-267, 1987
5. Heier MS, Aass N, Ous S, et al: Asymmetrical autonomic dysfunction of the feet after retroperitoneal surgery in patients with testicular cancer: 2 case reports. J Urol 147:470-471, 1992
6. Aprikian AG, Herr HW, Bajorin DF, et al: Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 74:1329-1334, 1994
7. Coogan CL, Hejase MJ, Wahle GR, et al: Nerve sparing postchemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 156:1656-1658, 1996
8. Hendry WF, Norman AR, Dearnaley DP, et al: Metastatic nonseminomatous germ cell tumors of the testis: Results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94:1668-1676, 2002
9. Jacobsen KD, Ous S, Waehre H, et al: Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer 80:249-255, 1999
10. Rabbani F, Goldenberg SL, Gleave ME, et al: Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: Is a modified dissection and resection of residual masses sufficient? Br J Urol 81:295-300, 1998
11. Debono DJ, Heilman DK, Einhorn LH, et al: Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455-1464, 1997
12. Napier MP, Naraghi A, Christmas TJ, et al: Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours. Br J Cancer 83:1274-1280, 2000
13. Steyerberg EW, Keizer HJ, Fossa SD, et al: Resection of residual retroperitoneal masses in testicular cancer: Evaluation and improvement of selection criteria-The ReHiT study group: Re-analysis of histology in testicular cancer. Br J Cancer 74:1492-1498, 1996
14. Toner GC, Panicek DM, Heelan RT, et al: Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 8:1683-1694, 1990
15. Steyerberg EW, Marshall PB, Keizer HJ, et al: Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: A decision analysis. Cancer 85:1331-1341, 1999
16. Fossa SD, Qvist H, Stenwig AE, et al: Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 10:569-573, 1992
17. Peckham MJ, McElwain TJ, Barrett A, et al: Combined management of malignant teratoma of the testis. Lancet 2:267-270, 1979
18. Mostofi FK: Comparison of various clinical and pathological classifications of tumors of testes. Semin Oncol 6:26-30, 1979
19. de Wit R, Roberts JT, Wilkinson PM, et al: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629-1640, 2001
20. Horwich A, Sleijfer DT, Fossa SD, et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15:1844-1852, 1997
21. Kaye SB, Mead GM, Fossa S, et al: Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16:692-701, 1998
22. Fossa SD, Ous S, Stenwig AE, et al: Distribution of retroperitoneal lymph node metastases in patients with non-seminomatous testicular cancer in clinical stage I. Eur Urol 17:107-112, 1990
23. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
24. Hendry WF, A'Hern RP, Hetherington JW, et al: Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: Prognostic value and therapeutic benefit. Br J Urol 71:208-213, 1993
25. Sheinfeld J, Bajorin D: Management of the postchemotherapy residual mass. Urol Clin North Am 20:133-143, 1993
26. Kuczyk M, Machtens S, Stief C, et al: Management of the postchemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT). Int J Cancer 83:852-855, 1999
27. Stenning SP, Parkinson MC, Fisher C, et al: Postchemotherapy residual masses in germ cell tumor patients: Content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 83:1409-1419, 1998
28. Fizazi K, Tjulandin S, Salvioni R, et al: Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy-Results from an international study group. J Clin Oncol 19:2647-2657, 2001
29. Lien HH, Stenwig AE, Ous S, et al: Influence of different criteria for abnormal lymph node size on reliability of computed tomography in patients with non-seminomatous testicular tumor. Acta Radiol Diagn (Stockh) 27:199-203, 1986
30. Steyerberg EW, Keizer HJ, Sleijfer DT, et al: Retroperitoneal metastases in testicular cancer: Role of CT measurements of residual masses in decision making for resection after chemotherapy. Radiology 215:437-444, 2000
31. Vugrin D, Whitmore W-FJ, Sogani PC, et al: Combined chemotherapy and surgery in treatment of advanced germ-cell tumors. Cancer 47:2228-2231, 1981
32. Logothetis CJ, Samuels ML, Trindade A, et al: The growing teratoma syndrome. Cancer 50:1629-1635, 1982
33. Donohue JP, Thornhill JA, Foster RS, et al: Clinical stage B non-seminomatous germ cell testis cancer: The Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A:1599-1604, 1995
34. Baniel J, Roth BJ, Foster RS, et al: Cost and risk benefit in the management of clinical stage II non-seminomatous testicular tumours. Cancer 75:2897-2903, 1995
35. Coogan CL, Foster RS, Rowland RG, et al: Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 50:957-962, 1997
36. Haaland CF, Dahl AA, Fossa SD: Quality of life in long-term survivors of testicular cancer. 18th International Union Against Cancer Congress, Oslo, Norway, June 30-July 5, 2002 (abstr 0124)
37. De Santis M, Bokemeyer C, Becherer A, et al: Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 19:3740-3744, 2001